Product Name: SykSubtide
Product Number: PE-01BJM85
Size: 200 µg      Price:41.00
1 mg      $US83.00
5 mg      179.00
Peptide Name: SykSubtide

Product Use: For assaying the phosphotransferase activity of Spleen protein-tyrosine kinase (UniProt ID P43405).

Peptide Production Method: Solid-phase peptide synthesis

Peptide Sequence: KKEEEDDDYEDPEEG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Molecular Mass Calculated: 1999.9 Da

Peptide Purity Percent after Synthesis and Purification: >80

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: Syk

Scientific Background: Syk is a protein-tyrosine kinase that is a member of the TK group of protein kinases in the Syk family. It is moderate to highly expressed in most tested human tissues, particularly in hematopoietic cells. It mediates cell proliferation, differentiation, and phagocytosis. In B cells, Syk plays a crucial role in intracellular signalling induced by oxidative stress as well as antigen receptor engagement. Syk is activated by phosphorylation at Y525 and Y526. Phosphorylation of Y348 and Y352 enhances the binding, phosphorylation and activation of PLC-gamma and the early phase of Ca(2+) mobilization via a PI 3-kinase-independent pathway. Phosphorylation of Y131 of Syk inhibits interaction with Bcr. Phosphorylation of Y323 of Syk inhibits B cell Ag receptor signalling and strongly dampens the Ca(2+) signal. Syk appears to be an oncoprotein (OP) and a tumour suppressor protein (TSP). Syk is an oncoprotein in retinoblastoma, which is upregulated and is required for tumour cell survival. Syk is a potential tumour suppressor in breast cancer, where it absence in primary breast tumours is correlated with poor outcomes. Syk deficient cells have increased motility that is restored to normalcy by replacement with wild-type Syk. It has been linked with the development of allergy, asthma, inflammation, gastric cancer, acute lymphoblastic leukemia, and acute myeloid leukemia.